NASDAQ:STRO Sutro Biopharma Q3 2026 Earnings Results & Report $9.59 -0.67 (-6.53%) Closing price 04:00 PM EasternExtended Trading$9.58 -0.01 (-0.10%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Sutro Biopharma missed analyst expectations on both earnings and revenue in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$1.90 versus the -$1.64 consensus estimate, while revenue of $9.10 million fell short of the $14.11 million estimate by $5.01 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeBefore Market OpensConference Call4:00 PM ET Sutro Biopharma EPS ResultsActual EPS-$1.90Consensus EPS -$1.64Beat/MissMissed by -$0.26One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersSutro Biopharma Revenue ResultsActual Revenue$9.10 millionExpected Revenue$14.11 millionBeat/MissMissed by -$5.01 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Sutro Biopharma Q3 2026 Earnings FAQ Did Sutro Biopharma beat earnings estimates for Q3 2026? Sutro Biopharma (NASDAQ:STRO) reported earnings of -$1.90 per share for Q3 2026, missing the consensus estimate of -$1.64. The report was announced on Thursday, November 12, 2026. What was Sutro Biopharma's revenue for Q3 2026? Sutro Biopharma reported revenue of $9.10 million for Q3 2026, against a consensus estimate of $14.11 million. Sutro Biopharma Earnings HeadlinesSutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights1 hour ago | globenewswire.comSutro Biopharma (NASDAQ:STRO) Cut to Strong Sell at Wall Street ZenNovember 8, 2026 | americanbankingnews.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 12 at 1:00 AM | Weiss Ratings (Ad)Sutro Biopharma to Participate in Upcoming Investor ConferencesNovember 4, 2026 | globenewswire.comWall Street Zen Upgrades Sutro Biopharma (NASDAQ:STRO) to "Sell"November 2, 2026 | americanbankingnews.comSutro’s New Phase 1 Cancer Study Puts STRO-006 in the SpotlightOctober 23, 2026 | tipranks.comSee More Sutro Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sutro Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sutro Biopharma and other key companies, straight to your email. Email Address About Sutro BiopharmaSutro Biopharma (NASDAQ:STRO) is a biotechnology company focused on discovering and developing targeted cancer treatments. Its research has centered on antibody-drug conjugates (ADCs), which use antibodies to deliver cancer-fighting drugs to selected cells. The company developed its XpressCF+ platform, a cell-free protein synthesis and site-specific conjugation technology intended to support the design and production of biologic medicines. Sutro’s clinical-stage programs have included luveltamab tazevibulin, an ADC targeting folate receptor alpha, and STRO-003, an ADC targeting ROR1. Based in South San Francisco, California, Sutro has conducted research and clinical development in oncology. Its programs and corporate circumstances may change as development progresses.View Sutro Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
